scholarly journals Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

2021 ◽  
Vol Volume 13 ◽  
pp. 8219-8230
Author(s):  
Ying-Tao Lin ◽  
Ying Chen ◽  
Tian-Xiu Liu ◽  
Fang Kuang ◽  
Ping Huang
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cost Effectiveness ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cost Effectiveness Analysis ◽  
Second Line ◽  
Second Line Therapy ◽  
Effectiveness Analysis ◽  
Line Therapy

scholarly journals Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

2021 ◽  
Vol 11 ◽  
Author(s):  
Qilin Zhang ◽  
Pan Wu ◽  
Xucheng He ◽  
Yufeng Ding ◽  
Yamin Shu
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cost Effectiveness ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cost Effectiveness Analysis ◽  
First Line ◽  
Lifetime Horizon ◽  
Effectiveness Analysis ◽  
Life Years

ObjectiveThe purpose of this cost-effectiveness analysis was to estimate the effects of adding camrelizumab to standard chemotherapy as the first-line treatment in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) on health and economic outcomes in China.MethodsA Markov model was developed to simulate the clinical course of typical patients with advanced or metastatic ESCC in the ESCORT-1st trial. Weibull survival model was employed to fit the Kaplan-Meier progression-free survival and overall survival probabilities of the camrelizumab-chemotherapy and placebo-chemotherapy strategy, respectively. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICER) were estimated over a 5-year lifetime horizon. Meanwhile, one-way and probabilistic sensitivity analyses were conducted to test the uncertainty in the model.ResultsOn baseline analysis, the incremental effectiveness and cost of camrelizumab-chemotherapy versus placebo-chemotherapy were 0.15 QALYs and $7,110.56, resulting in an ICER of $46,671.10/QALY, higher than the willingness-to-pay (WTP) threshold of China ($31,498.70/QALY). The results were sensitive to the utility of PFS and cost of camrelizumab.ConclusionThe findings from the present analysis suggest that the addition of camrelizumab to chemotherapy might not be cost-effective in patients with advanced or metastatic ESCC in China.

Sign in / Sign up

Export Citation Format

Share Document